by Amy Green
Health ENews, February 16, 2017

2 pp. 72 kB

Interim results from the Nix-TB trial, which were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle, are extremely promising and point to new hope for people diagnosed with XDR-TB. According to the TB Alliance, the organisation conducting the trial, the “vast majority” of patients with XDR-TB in the study were “clinically well” and “able to go home to their families” after completing just six months of treatment with a new drug regimen (bedaquiline and pretomanid together with linezolid).

(Visited 17 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.
Facebook Auto Publish Powered By :
Get the latest issue of the NewsletterDownload